Biologics Development Solutions for Companion Animal Therapeutics

Biologics Development Solutions for Companion Animal Therapeutics
Product Description

Leverages advanced expression technologies, optimised vectors, and flexible bioprocessing platforms to deliver scalable and cost‑efficient solutions tailored to companion animal biologics. Supports from early development to GMP manufacturing, with customisation for veterinary specific requirements.

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO
Specifications
  • CAS Registry Number
    N/A
  • Details
    Therapeutic monoclonal antibodies, polyclonal antibodies, recombinant proteins for companion animals (e.g., dogs, cats); covers molecular design, expression optimisation, cell line development, process development, and scale‑up.

  • Selling Points
    Leverages human biologics technology platforms to ensure high quality for veterinary products, accelerating time‑to‑market for companion animal therapeutics.

  • Model
    Customised expression platform (antibodies/recombinant proteins)
  • Supplied from
    China
  • Measured In
    Container

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO

More Products from Canton Biologics (2)

  • Biomedical and Healthcare Recombinant Protein Solutions

    Product Biomedical and Healthcare Recombinant Protein Solutions

    Combines molecular engineering, host cell optimisation, expression system development, and process optimisation to address complex protein structures. The IgMax® platform enables production of pentameric IgM at high expression levels, with near‑complete pentamer assembly and excellent purity after downstre...
  • Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

    Product Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

    Integrated development and manufacturing solutions combining molecular engineering, vector optimization, host cell engineering, and customized process development. The platform delivers high titers for mAb production, and DTEasy™ strategies have demonstrated significant yield improvements across various di...